---
title: Lifemel Honey to Reduce Leucopenia During Chemotherapy
nct_id: NCT00243165
overall_status: UNKNOWN
phase: PHASE2
sponsor: Rambam Health Care Campus
study_type: INTERVENTIONAL
primary_condition: Breast Cancer
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00243165.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00243165"
ct_last_update_post_date: 2009-12-07
last_seen_at: "2026-05-12T07:18:07.985Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Lifemel Honey to Reduce Leucopenia During Chemotherapy

**Official Title:** Lifemel Honey During Adjuvant Chemotherapy for Breast Cancer Patients to Prevent Leucopenia

**NCT ID:** [NCT00243165](https://clinicaltrials.gov/study/NCT00243165)

## Key Facts

- **Status:** UNKNOWN
- **Phase:** PHASE2
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 60
- **Lead Sponsor:** Rambam Health Care Campus
- **Collaborators:** Zuf Globus Laboratories Ltd.
- **Conditions:** Breast Cancer
- **Start Date:** 2005-11
- **CT.gov Last Update:** 2009-12-07

## Brief Summary

This study will include 60 patients with early breast cancer referred to receive adjuvant chemotherapy with AC ( adriamycin- cyclophosphamide) or CAF ( adriamycin- cyclophosphamide- 5- fluorouracil ) combinations. These patients will receive every day one spoon of Lifemel honey or regular honey ( double blind)- during the adjuvant chemotherapy .Every week a WBC count will be performed in order to record the influence of Lifemel on myelotoxicity.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** FEMALE
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* breast cancer patient treated with adjuvant chemotherapy
* PS = 2 or less

Exclusion Criteria:

* none
```

## Interventions

- **Lifemel honey intake every day** (BEHAVIORAL)

## Primary Outcomes

- **Prevention of myelotoxicity-every week during chemotherapy.**

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT00243165.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT00243165*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*